Figure 2
Figure 2. OS in 291 patients with relapse during or after chemotherapy, no Ph+ ALL, and no CNS involvement for whom data were available. (A) OS according to age: 15-25 years of age, n = 107 (solid line), 38% ± 2% after 3 years, median 14.4 months; 26-45 years of age, n = 129 (short dashed line), 28% ± 4% after 3 years, median 28.5 months; and 46-55 years of age, n = 55 (long dashed line), 12% ± 5% after 3 years, median 6.1 months (P < .0001). (B) OS according to time to relapse: < 18 months, n = 200 (solid line), 22% ± 3% after 3 years, median 8.3 months; > 18 months, n = 91 (dashed line), 43% ± 6% after 3 years, median 19.7 months (P < .0001).

OS in 291 patients with relapse during or after chemotherapy, no Ph+ ALL, and no CNS involvement for whom data were available. (A) OS according to age: 15-25 years of age, n = 107 (solid line), 38% ± 2% after 3 years, median 14.4 months; 26-45 years of age, n = 129 (short dashed line), 28% ± 4% after 3 years, median 28.5 months; and 46-55 years of age, n = 55 (long dashed line), 12% ± 5% after 3 years, median 6.1 months (P < .0001). (B) OS according to time to relapse: < 18 months, n = 200 (solid line), 22% ± 3% after 3 years, median 8.3 months; > 18 months, n = 91 (dashed line), 43% ± 6% after 3 years, median 19.7 months (P < .0001).

Close Modal

or Create an Account

Close Modal
Close Modal